Ocean Biomedical, Inc. financial data

Symbol
OCEA, OCEAW on Nasdaq
Location
515 Madison Ave Suite 8078, New York, NY
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Ocean Biomedical, Inc./DE (to 2/15/2023), Aesther Healthcare Acquisition Corp. (to 2/14/2023)
Latest financial report
10-Q - Q3 2023 - Apr 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 5.5 % -96%
Debt-to-equity -103 % -121%
Return On Equity 162 %
Return On Assets -6.16K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 34.6M shares +2.59%
Common Stock, Shares, Outstanding 34.1M shares
Entity Public Float 107M USD
Weighted Average Number of Shares Outstanding, Basic 26.6M shares +13.9%
Weighted Average Number of Shares Outstanding, Diluted 26.6M shares +13.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 305K USD -83.6%
General and Administrative Expense 2.35M USD +78.7%
Operating Income (Loss) 1.83M USD +16.3%
Nonoperating Income (Expense) -11.4M USD -2209%
Net Income (Loss) Attributable to Parent -82.2M USD -284%
Earnings Per Share, Basic -0.53 USD/shares -231%
Earnings Per Share, Diluted -0.53 USD/shares -231%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 0 USD
Assets, Current 1.03M USD +71.9%
Assets 1.03M USD -99.1%
Accounts Payable, Current 16M USD +8765%
Accrued Liabilities, Current 804K USD -6.53%
Liabilities, Current 30.9M USD +1375%
Liabilities 76.3M USD +1355%
Retained Earnings (Accumulated Deficit) -179M USD -7652%
Stockholders' Equity Attributable to Parent -75.2M USD -665%
Liabilities and Equity 1.03M USD -99.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.65M USD -622%
Net Cash Provided by (Used in) Financing Activities 2.92M USD +388%
Common Stock, Shares Authorized 300M shares
Common Stock, Shares, Issued 34.1M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 272K USD +17.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1M USD
Deferred Tax Assets, Valuation Allowance 180K USD +52.5%
Deferred Tax Assets, Gross 180K USD +52.5%
Deferred Tax Assets, Operating Loss Carryforwards 478K USD -15.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares +700%
Additional Paid in Capital 104M USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 186K USD -93.7%
Interest Expense 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%